- Home
- Agenda
- Clinical 2.0 Track
- Comparing and Contrasting Global Regulatory Requirements for Clinical Evaluation Reports (CERs). Highlighting: Japan, China, Europe, Australia and ASAEN
- Health Economics Analyses and its Role in Medical Device Adoption
- Avoiding Pitfalls and Mitigating Risk Throughout a Clinical Trial
- U.S. FDA Advisory Panel Meetings: Strategies to Maximize Success
- Technology Track
- Ecosystem Track
- The Changing Face of MedTech: Attracting and Keeping an Inclusive Workforce
- Strategies for Today’s Funding Landscape
- Getting to the Exit
- Meet Your Local MedTech Reporters
- From Mind to Matter: Addressing the Opioid Crisis Through a Hands-On User-Centered Innovation Process
- Provider Perspectives: What Do Our Customers Want?
- Regulatory 2.0
- FDA Strategic Initiatives
- Digital Health and Software as a Medical Device (SaMD)
- Real World Evidence / Patient Preference Initiative
- Novel Pathways to FDA and CMS Approval: Parallel Review in Medical Devices
- Transitioning from MDD to MDR: How is this REALLY rolling out? Tips, Tricks, and Lessons Learned from Large Program Implementation
- Portfolio Planning as an input to your EU MDR implementation plan. Which devices should stay and which should go? Balancing the cost and effort of transitioning to the EU MDR with product life cycle planning and revenue expectations
- Achieving MEDDEV 2.7/1 Rev. 4 and EU MDR Compliant Clinical Evaluation Reports (CERs): What We’ve Learned From Completing 100+
- Post market surveillance under EU MDR – do I have to run a clinical study? What other options do you have to fulfill post market surveillance requirements; including updating CERs
- Keynotes
- Clinical 2.0 Track
- Events
- Exhibitors
- Travel
|